AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02378623 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients who meet the study eligibility criteria and consent for enrollment will be randomized in a 1:1 ratio to intervention with apixaban or control group with placebo. The randomization will be performed by a computer generated block randomization protocol. Randomization will be stratified according to pre-existing CIED (≥6 months) vs. new implantation (\<6 months from date of implant), in order to ensure at least 25% of patients have longstanding lead placement.
Study NCT02245178 — intervention group
Intervention type: PROCEDURE
Intervention: Lung spirometry
Description: measurement of pulmonary function pre- and post-bronchodilator
Study NCT02245178 — intervention group
Intervention type: OTHER
Intervention: CT scan analysis
Description: Analysis of existing year 25 thoracic CT scans for lung and intrathoracic vascular structure
Study NCT00972088 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: capsule endoscopy
Description: The disposable, ingestible PillCam® SB2 Capsule acquires the video images during natural propulsion through the digestive system. The Capsule transmits the acquired images via digital radio frequency communication channel to the Given® Data Recorder unit located outside the body.
Study NCT03194529 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMT
Description: Fecal Microbiota Transplantation, single dose, 50g of stool, delivered via standard of care upper endoscopy into jejunum.
Study NCT00027300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natalizumab
Description: Natalizumab 300 mg IV infusion, every 4 weeks, for up to 116 weeks.
Study NCT00027300 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, IV infusion, every 4 weeks, for up to 116 weeks.
Study NCT03092193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: 20 phenotyped for CYP2C9 and CYP2C19 (by PCR) and for the pharmacokinetics of naproxen, saliva samples will be collected of these patients at different times after ingestion of a tablet of naproxen (500mg) (before, 0,25; 0,5; 0,75; 1; 1,5; 2; 3; 4; 5; 6; 8; 11; 24; 48; 72 e 96 hours after ingestion).
Study NCT03092193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen-esomeprazole
Description: 20 phenotyped for CYP2C9 and CYP2C19 (by PCR) and for the pharmacokinetics of naproxen-esomeprazole, saliva samples will be collected of these patients at different times after ingestion of a tablet of naproxen-esomeprazole (500mg+20mg) (after one month of the first collection) (before, 0,25; 0,5; 0,75; 1; 1,5; 2; 3; 4; 5; 6; 8; 11; 24; 48; 72 e 96 hours after ingestion).
Study NCT01346592 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent split influenza vaccine (TIV)
Study NCT01346592 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MF59-adjuvanted trivalent influenza vaccine (aTIV)
Study NCT01346592 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed comparator trivalent split influenza vaccine (comparator TIV)
Study NCT00773461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8mg/kg iv every 4 weeks for 24 weeks
Study NCT00773461 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: iv every 4 weeks for 24 weeks
Study NCT05040399 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Locking Compression Plates
Description: Plates and screws for sternal fixation
Study NCT05040399 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sternal Wires
Description: sternal wires used for fixation of sternum
Study NCT03925064 — intervention group
Intervention type: OTHER
Intervention: myocardial performance index
Description: fetal right ventricular myocardial performance index measured with tissue doppler
Study NCT00895856 — intervention group
Intervention type: OTHER
Intervention: Evaluation of the functional capacity
Description: An evaluation (questionnaire) was performed by the Katz Index of individuals in this group, including personal issues (sex and age) and different levels of functional independence for the elderly in their basic activities of daily living (ABVD's) such as: bathe, dress, use the bathroom for withdrawals, transfers perform, has control of the sphincters and the food itself. Subject themselves, if capable of responding to the issues of consistency index, did. The answers were given to the auxiliary nurse responsible for care to residents.
Study NCT01502280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Aminolevulinic acid (ALA)
Description: Following informed consent, within 3 hours prior to surgery, patient will orally ingest \[or be given via Nasogastric (NG), Orogastric (OG), or Gastric tube (G-tube)\] either (1) 5-ALA/Gliolan® mixed with sterile water (20mg/kg)
Study NCT01502280 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - ascorbic acid
Description: Within 3 hours prior to surgery, patient will orally ingest \[or be given via Nasogastric (NG), Orogastric (OG), or Gastric tube (G-tube)\] 1.5 Gm. placebo - ascorbic acid in 50 ml sterile water.
Study NCT00572897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine, Melphalan +/- ATG
Description: Conditioning regimen for Allogenic Stem Cell Transplant:~Related Donor Fludarabine days -6 to -2 (30mg/m2 IVPB over 30 minutes daily) Melphalan days -3 to -2 (70mg/m2 IVPB over 30 minutes daily)~Unrelated Donor Fludarabine days -6 to -2 (30mg/m2 IVPB over 30 minutes daily) Melphalan days -3 to -2 (70mg/m2 IVPB over 30 minutes daily) ATG (Thymoglobulin®) days -3 to -1 (0.5 mg/kg IV on day -3 \[given over 6 hours\], and 2 mg/kg on days -2 and -1 \[given over 4 hours\])
Study NCT03438383 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bi-PAP
Description: The Bi-PAP system combines inspiratory support-IPAP (inspiratory positive airway pressure) with expiratory support-EPAP (expiratory positive airway pressure) and has been used, with good results, in a number of different clinical conditions such as COPD, respiratory failure due to neuromuscular disease, cardiogenic pulmonary edema and immediately post-operatively with pro-phylactic purpose.
Study NCT03438383 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Bi-PAP
Description: Sham Bi-PAP was created by introducing a hole at the connection of the mask with the spiral tube of the conventional Bi-PAP system. By doing so, the applied pressure by sham Bi-PAP was constant and equal to 2 cm H2O.
Study NCT01047735 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-en-Y Gastric Bypass Surgery
Description: Participants assigned to the Roux-en-Y Gastric Bypass treatment group will undergo a surgical procedure that limit foods intake and causes nutrients malabsorption. The procedure is performed with small incisions or laparoscopically. A small stomach pouch is created, the size of an egg, and the small intestine is connected to the pouch. Some of the stomach and small intestine are consequently bypassed by this anatomic change. Those in this treatment group will begin a gradual diet post surgery and will take life long vitamin supplements.
Study NCT01047735 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Adjustable Gastric Banding
Description: Those assigned to the Laparoscopic Adjustable Gastric Banding study group will undergo a surgical procedure where an adjustable silicone band is placed around the upper stomach to decrease its capacity so that you will feel full sooner. It will assist in weight loss by helping you to limit intake of calories. The band will be placed by using several small incisions and telescopic instruments. A thin tube connects the band to an access port just under the skin that you may be able to feel but you will not be able to see it. This allows the band to be tightened or loosened to decrease or increase your stomach capacity as needed. The surgery will take on average 30-45 minutes.
Study NCT01047735 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Weight Loss Intervention
Description: Participants will receive a standard behavior weight control program in an in-person format over a period of 12 months conducted by an experienced team of weight loss counselors. During the initial 6 months of study treatment, will attend weekly in-person individual sessions with a weight loss counselor. During months 7-12, will attend in-person sessions on the 1st and 3rd week of the month and will receive a brief (less than 10 minutes in duration) telephone call on the 2nd and 4th week of the month. Each session will focus on a specific behavioral topic related to weight loss, eating behaviors, or exercise behaviors.
Study NCT04283409 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graded activity
Description: Exercise therapy using principles of cognitive behavioral therapy and education
Study NCT04283409 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Control Exercises
Description: Exercise therapy using principles of motor control and motor learning and education
Study NCT03808922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAS181
Description: DAS181 4.5mg nebulized qd x 7 OR 10 days
Study NCT03808922 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nebulized qd x 7 OR 10 days
Study NCT03808922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAS181 COVID-19
Description: DAS181 4.5mg nebulized q12h/day x 7 OR 10 days
Study NCT03808922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAS181 OL
Description: DAS181 4.5mg nebulized qd x 7 OR 10 days ≥ 40kg DAS181 2.5mg nebulized qd x 7 OR 10 days \< 40kg
Study NCT01503177 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oncolytic measles virus encoding thyroidal sodium iodide symporter
Description: Given intrapleurally
Study NCT01503177 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01503177 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single photon emission computed tomography
Description: Correlative studies
Study NCT01503177 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Correlative studies
Study NCT04548219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Reference and test formulations of mirikizumab administered as a SC injection.
Study NCT00190528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy + radical hysterectomy
Study NCT00190528 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radical hysterectomy
Study NCT02067598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scapular exercise
Study NCT04178473 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total abdominal hysterectomy
Description: total abdominal hysterectomy at time of sacrocolpopexy
Study NCT04178473 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subtotal abdominal hysterectomy
Description: Subtotal abdominal hysterectomy at time of sacrocolpopexy
Study NCT04046562 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PAW
Description: Pain and Weight Treatment plus standard of care
Study NCT04046562 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Pain Education
Description: Pain Education plus standard of care
Study NCT03768570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: 1500 mg IV on day 1 of 4 week cycle every 4 weeks for 12 months
Study NCT04169100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: We propose to test whether QT prolongation is reversible with moderate doses of prednisone in patients with QT interval greater than 500 msec.
Study NCT04568993 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proximal phalangeal level
Description: Injection of methyl prednisone and lidocaine in the tendon sheet at the level of the proximal phalanx
Study NCT04568993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Volar to the MCP-joint
Description: Injection of methyl prednisone and lidocaine in the tendon sheet volar to the MCP-joint
Study NCT01093638 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral Formulation of Insulin
Description: Oral formulation of insulin fed concomitantly with infant formula
Study NCT01093638 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral formulation of placebo fed concomitantly with infant formula
Study NCT03827837 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
Study NCT02006290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06412562
Description: single oral split dose 30+20 mg QD
Study NCT02006290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet, matching placebo, QD
Study NCT03827837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: a small-molecule multikinase inhibitor
Study NCT01163266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Encapsulated vortioxetine immediate release tablets
Study NCT04425577 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Transabdominal Ultrasound
Description: Transabdominal Ultrasound
Study NCT02183376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356
Study NCT02926170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban will be started at 20 mg/day. Dose will be adjusted according to Cr Clearance. Cr Clearance 30-49 ml/min will receive 15 mg/day.
Study NCT02926170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acenocumarol
Description: Doses will be adjusted according to INR
Study NCT04677686 — intervention group
Intervention type: BEHAVIORAL
Intervention: Bundle of Care
Description: Hair removal with Clipper Glucose Control Preoperative antibiotics Repeat antibiotics after 4 Hours Optimize Body temperature Instrument change for colorectal anastomosis Use of wound protectors Experienced surgeon Preoperative showering
Study NCT03109041 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CivaSheet
Description: The FDA Cleared CivaSheet Directional Pd103 Brachytherapy Source is a planar radiation source which utilizes gold shielding in its construction. This device is radioactive on one side only, and is capable of safely delivering high doses of radiation to target areas even when placed directly adjacent to sensitive, healthy tissue or critical structures.
Study NCT01163266 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vortioxetine placebo-matching capsules
Study NCT02765685 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: brace ODRA (PROTEOR company)
Description: Port of the orthosis ODRA during day during 12 months, Complement to their usual care. The subjects will have for instruction to wear the brace a minimum of 6 hours a day, 5 days a week, And to remove it during the rest periods in lengthened position.
Study NCT02765685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: The patients will benefit only from the coverage proposed usually, by their regular doctor and according to the notices of the medical and paramedical specialists taking care of this pathology (physiotherapists, orthopaedic osteopaths, sports medicine physician, surgeon, rheumatologists, rehabilitative doctors, etc.). In the absence of recommendations on the modalities of coverage of the gonarthrose and in front of diverse clinical habits, the usual said coverage can be at the same time medicinal (anti-inflammatory, painkilling, ...), non-medicinal (physiotherapy, port of an orthosis, ...), even surgical, according to the influencers.
Study NCT02765685 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The patients will benefit only from the coverage proposed usually, by their regular doctor and according to the notices of the medical and paramedical specialists taking care of this pathology (physiotherapists, orthopaedic osteopaths, sports medicine physician, surgeon, rheumatologists, rehabilitative doctors, etc.). In the absence of recommendations on the modalities of coverage of the gonarthrose and in front of diverse clinical habits, the usual said coverage can be at the same time medicinal (anti-inflammatory, painkilling, ...), non-medicinal (physiotherapy, port of an orthosis, ...), even surgical, according to the influencers.
Study NCT04620655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RD13-01 cell infusion
Description: Universal CAR-T cells targeting CD7
Study NCT04132427 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: vancomycin, magnesium citrate, microbiota
Description: 10 days of oral vancomycin, then 1 day of oral magnesium citrate, , then 4 days of high-dose oral microbiota, followed by 12 weeks of low-dose oral microbiota
Study NCT04132427 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: placebo vancomycin, real magnesium citrate, placebo microbiota
Description: 10 days of oral placebo vancomycin, then 1 day of oral real magnesium citrate, , then 4 days of high-dose oral placebo microbiota, followed by 12 weeks of low-dose oral placebo microbiota
Study NCT02343250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilnidipine/Valsartan
Description: Cilnidipine 10mg/Valsartan 160mg oral on day1 of 14day cycle
Study NCT02343250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilnidipine+Valsartan
Description: Cinidipine 10mg+Valsartan 160mg oral on day1 of 14day cycle
Study NCT02343250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilnidipine/Valsartan
Description: Cilnidipine 10mg/Valsartan 160mg oral on day1 of 14day cycle
Study NCT02343250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilnidipine+Valsartan
Description: Cinidipine 10mg+Valsartan 160mg oral on day1 of 14day cycle
Study NCT00609154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glucagon like peptide-1
Description: GLP-1 1 pmole/kg/min
Study NCT00609154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glucagon like peptide-1
Description: GLP-1 1 pmole/kg/min
Study NCT00609154 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: glucose control
Description: glucose without GLP-1
Study NCT00609154 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: glucose control
Description: glucose without GLP-1
Study NCT03388008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Belatacept will be dosed at 10 mg/kg of actual body weight on days 0, 7, 14, 28, 56, and 84 then at 5 mg/kg on day 112 and every 28 days through day 364 (i.e., on days 140, 168, 196, 224, 252, 280, 308, 336, and 364)
Study NCT03388008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus will be dosed enterally or sublingually within 48 hours of transplantation and the dose will be adjusted to target a trough blood level of 8-15 ng/ml
Study NCT03388008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: Anti-thymocyte globulin will be dosed intravenously at 3 mg/kg divided into 3 daily doses starting on day 0 after transplantation
Study NCT03388008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATG
Description: Anti-thymocyte globulin will be dosed intravenously at 3 mg/kg divided into 3 daily doses starting on day 0 after transplantation
Study NCT03388008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate mofetil will be dosed at 1000 mg twice daily (or if the enteric coated formulation is used, this will be dosed at 720 mg twice daily. In the standard of care arm, mycophenolate mofetil will be initiated on day 0 after transplantation, whereas in the belatacept-based immunosuppression arm, mycophenolate mofetil will be initiated on day 90 after transplantation
Study NCT03388008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Mycophenolate mofetil will be dosed at 1000 mg twice daily (or if the enteric coated formulation is used, this will be dosed at 720 mg twice daily. In the standard of care arm, mycophenolate mofetil will be initiated on day 0 after transplantation, whereas in the belatacept-based immunosuppression arm, mycophenolate mofetil will be initiated on day 90 after transplantation
Study NCT03388008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone 500 mg will be given intravenously before perfusion of the allograft during the transplant procedure, then methylprednisolone 0.5 mg/kg will be given intravenously twice daily for 6 total doses
Study NCT03388008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone 500 mg will be given intravenously before perfusion of the allograft during the transplant procedure, then methylprednisolone 0.5 mg/kg will be given intravenously twice daily for 6 total doses
Study NCT03388008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be dosed at 0.5 mg/kg orally daily through day 14, then 0.2 mg/kg orally daily through day 30, then 0.1 mg/kg daily through day 180, then 5 mg daily through day 365